124 related articles for article (PubMed ID: 38185345)
1. Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction.
Abdel-Rahman SA; Santini BL; Calvo-Barreiro L; Zacharias M; Gabr M
Bioorg Med Chem Lett; 2024 Feb; 99():129599. PubMed ID: 38185345
[TBL] [Abstract][Full Text] [Related]
2. First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators.
Abdel-Rahman SA; Świderek K; Gabr MT
RSC Med Chem; 2023 Sep; 14(9):1767-1777. PubMed ID: 37731692
[TBL] [Abstract][Full Text] [Related]
3. Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.
Le KS; Thibult ML; Just-Landi S; Pastor S; Gondois-Rey F; Granjeaud S; Broussais F; Bouabdallah R; Colisson R; Caux C; Ménétrier-Caux C; Leroux D; Xerri L; Olive D
Cancer Res; 2016 Aug; 76(16):4648-60. PubMed ID: 27246829
[TBL] [Abstract][Full Text] [Related]
4. Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.
Han Y; Dong Y; Yang Q; Xu W; Jiang S; Yu Z; Yu K; Zhang S
Front Immunol; 2018; 9():2227. PubMed ID: 30319662
[TBL] [Abstract][Full Text] [Related]
5. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.
Amatore F; Gorvel L; Olive D
Expert Opin Ther Targets; 2018 Apr; 22(4):343-351. PubMed ID: 29468927
[TBL] [Abstract][Full Text] [Related]
6. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
Boggio E; Gigliotti CL; Moia R; Scotta A; Crespi I; Boggione P; De Paoli L; Deambrogi C; Garzaro M; Vidali M; Chiocchetti A; Stoppa I; Rolla R; Dianzani C; Monge C; Clemente N; Gaidano G; Dianzani U
Br J Haematol; 2022 Mar; 196(6):1369-1380. PubMed ID: 34954822
[TBL] [Abstract][Full Text] [Related]
7. Inducible costimulator (ICOS) and ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production.
Maeda S; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K; Hasegawa M
Am J Pathol; 2011 Nov; 179(5):2360-9. PubMed ID: 21925472
[TBL] [Abstract][Full Text] [Related]
8. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway.
Tanaka C; Fujimoto M; Hamaguchi Y; Sato S; Takehara K; Hasegawa M
Arthritis Rheum; 2010 Jun; 62(6):1723-32. PubMed ID: 20191584
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Zhan XK; Liu XK; Zhang S; Chen H
Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of ICOS ligand by interaction with ICOS functions as a regulatory mechanism for immune responses.
Watanabe M; Takagi Y; Kotani M; Hara Y; Inamine A; Hayashi K; Ogawa S; Takeda K; Tanabe K; Abe R
J Immunol; 2008 Apr; 180(8):5222-34. PubMed ID: 18390703
[TBL] [Abstract][Full Text] [Related]
11. Inducible T-Cell Costimulator Mediates Lymphocyte/Macrophage Interactions During Liver Repair.
Ramavath NN; Gadipudi LL; Provera A; Gigliotti LC; Boggio E; Bozzola C; Albano E; Dianzani U; Sutti S
Front Immunol; 2021; 12():786680. PubMed ID: 34925367
[TBL] [Abstract][Full Text] [Related]
12. Protective Role of ICOS and ICOS Ligand in Corneal Transplantation and in Maintenance of Immune Privilege.
Kunishige T; Taniguchi H; Terada M; Akiba H; Yagita H; Abe R; Hori J
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6815-6823. PubMed ID: 28002569
[TBL] [Abstract][Full Text] [Related]
13. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.
Amatore F; Gorvel L; Olive D
Expert Opin Biol Ther; 2020 Feb; 20(2):141-150. PubMed ID: 31738626
[No Abstract] [Full Text] [Related]
14. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Solinas C; Gu-Trantien C; Willard-Gallo K
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
[TBL] [Abstract][Full Text] [Related]
15. ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.
Alves GF; Stoppa I; Aimaretti E; Monge C; Mastrocola R; Porchietto E; Einaudi G; Collotta D; Bertocchi I; Boggio E; Gigliotti CL; Clemente N; Aragno M; Fernandes D; Cifani C; Thiemermann C; Dianzani C; Dianzani U; Collino M
Front Immunol; 2022; 13():992614. PubMed ID: 36119089
[TBL] [Abstract][Full Text] [Related]
16. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.
Hasegawa M; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K
Rheumatology (Oxford); 2013 Feb; 52(2):242-51. PubMed ID: 23024058
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of inducible costimulator ligand costimulatory function: determination of the cell surface oligomeric state and functional mapping of the receptor binding site of the protein.
Chattopadhyay K; Bhatia S; Fiser A; Almo SC; Nathenson SG
J Immunol; 2006 Sep; 177(6):3920-9. PubMed ID: 16951355
[TBL] [Abstract][Full Text] [Related]
18. T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T-cell costimulator.
Jiao Q; Qian Q; Liu C; Luo Y; Fang F; Wang M; Ji J; Qian H; Zhang X; Maurer M
Br J Dermatol; 2020 Mar; 182(3):648-657. PubMed ID: 31090221
[TBL] [Abstract][Full Text] [Related]
19. ICOS/ICOSL upregulation mediates inflammatory response and endothelial dysfunction in type 2 diabetes mellitus.
Zhang HY; Ruan LB; Li Y; Yang TR; Liu WJ; Jiang YX; Li TR; Quan J; Xuan W
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8898-8908. PubMed ID: 30575933
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells regulate type 2 innate lymphoid cells via regulatory T cells through ICOS-ICOSL interaction.
Fan X; Xu ZB; Li CL; Zhang HY; Peng YQ; He BX; Liu XQ; Chen DH; Chen D; Akdis CA; Fu QL
Stem Cells; 2021 Jul; 39(7):975-987. PubMed ID: 33662168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
